Weekly Digest - October 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2024
10 Oct 2024: AstraZeneca’s dual-antibody ADC approved for two clinical trials in China
- AstraZeneca’s innovative drug AZD9592 has received implicit licensing for two clinical trials in China, targeting advanced solid tumors in combination with osimertinib and with 5-Fluorouracil, leucovorin, and bevacizumab
- AZD9592 is a bispecific ADC targeting both EGFR and c-MET, developed to deliver cytotoxic drugs directly to cancer cells
- Preclinical data indicates that AZD9592 has a promising efficacy and safety profile for tumors expressing EGFR and c-MET, particularly in adenocarcinoma, squamous non-small cell lung cancer, and head and neck squamous cell carcinoma
- A Phase 1 trial is underway to assess AZD9592 as a monotherapy and in combination with other anti-cancer agents for advanced solid tumors
